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INTRODUCTION 
Every pregnant women desire a healthy child who is free of 
anomalies. The incidence of major malformation in newborn is about 
3-5%. Ultrasonogram plays a central role in the provision of prenatal 
screening and diagnosis. 
 
Since Professor. Ion Donald introduced ultrasound in to 
obstetrics in the late 1950’s vast improvement has been made in the 
ultrasound technology. This revolutionary technological 
improvements and the use of high frequency transvaginal scanning 
have allowed the resolution of ultrasound imaging in the first 
trimester to evolve to the stage where detailed early fetal development 
can be well visualized. 
 
The early first trimester scan was initially introduced with the 
primary intention of measuring the fetal crown – rump length to 
achieve accurate pregnancy dating. Besides, imaging technology has 
also made it possible to accurately diagnose chromosomal 
abnormalities and structural anomalies before the second trimester. 
 
Based on Radius Trial, the routine anomaly scan was done at 
18-22 weeks but now the emphasis for screening for fetal 
abnormalities have been moved to the first trimester 11-14 weeks. 
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Until recently, attempt to detect fetal disorders during the first 
trimester have been confined to high risk & selected population. 
Evidences prove that routine early ultrasonography in screening low 
risk pregnancies for fetal defects is beneficial . 
 
The early ultrasound screening has various advantages like  
a) It provides reassurance to the patient and also to the obstetrician. 
b) It provides information about specific abnormalities or aneuploidy. 
c) It provides opportunity for prenatal invasive testing. 
d) It helps in deciding for early termination. 
e) It provides knowledge of the condition that may  affect future 
pregnancies’ and necessitate counseling. 
 
The 11-13 week window of gestation age is the best to assess 
gestational age, measure Nuchal translucency thickness and obtain a 
potentially detailed anatomic survey. (Whitlow et al :1998)1.A more 
thorough examination of the fetal anatomy is performed when 
mandated by the patients  history of an abnormal finding on a 
screening examination. 
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AIM OF THE STUDY 
 
To assess the value of performing a detailed examination of the 
fetus for both structural anomalies and markers of aneuploidy as a 
part of routine 11 to 13 weeks ultrasound  scan in a two stage 
screening process in the general obstetric population. 
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REVIEW OF LITERATURE 
 
ULTRASOUND AND ITS PRINCIPLES 
Ultrasound is defined as the sound above the range of human 
hearing that is above the frequency of 20,000 Hz – Normal human 
frequency range is between 20 Hz – 20,000 Hz. Ultrasound imaging is 
based on the same principle involved in the sonar used by bats, ship 
and fishermen. When a sound wave strikes an object, it bounces back, 
or echo’s. The transducer sends the sound waves and records the 
echoing waves. When the transducers is pressed against the skin, it 
directs small pulses of inaudible, high frequency sound wave in to the 
body. As the sound waves bounces off of the internal organs, fluids 
and tissues, the sensitive microphone in the transducer records tiny 
changes in the sounds pitch which are instantly measured and 
displayed by a computer which in turn create the real time picture on 
the monitor. 
 
HISTORY OF ULTRASOUND 
The History of ultrasound can be traced to Spallanzovi. In 1970 
he experimented with bats and found that they maneuver through the 
air using their hearing rather then an sight. Jean – Daniel colladon in 
1826 discovered sonography with an under water bell and determined 
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the speed of sound through water. The major step in the history of 
ultrasound was the invention of the transducer by Paul Langevin. 
 
ULTRASOUND IN OBSTETRICS 
Professor Ion Donald was the first person to use ultrasound as a 
diagnostic tool in obstetric in 1950 and was called the “Father of 
Obstetric ultrasound”. In 1972 the first prenatal diagnosis of a 
congenital anomaly by USG was made by Campbell which altered the 
Obstetric Management. 
 
Ultrasound has become an  integral component of Obstetric 
care, with the vast majority of patients having at least one ultrasound 
examination during pregnancy. Recent advances in obstetricUSG have 
increased its importance in managing pregnancy at risk for 
aneuploidy, structural anomalies, pre term delivery and blood flow 
abnormalities. First trimester USG was traditionally used to assess 
fetal viability and accurately date the pregnancy. More recently the 
introduction of screening for fetal nuchal translucency thickness has 
resulted in many more women having a scan in early pregnancy. Once 
an anomaly is detected, it allows the chance for early termination. 
Prenatal diagnosis not only allows termination but has profound 
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implication on antenatal and intrapartum management such as in-utero 
treatment of diaphragmatic hernia and other fetal therapy. 
 
Prenatal diagnosis of anomaly was routinely performed in 18-22 
weeks but now due to advancement in resolution in ultrasound the 
diagnosis of structural anomaly can be done in the first trimester. The 
timing of ultrasound examination depends upon the gestational age at 
which the organs are expected to developed. Most fetal structures are 
visualized at approximately 12-13 weeks and hence early detailed 
USG is technically feasible as a screening test for fetal structural 
defect.  
 
Green and Hobbins (1988)2 commented that with the greater 
resolution of modern day ultrasound a detailed fetal anatomy could be 
visualized with TAS in the first trimesters. Transvaginal sonogram 
has superior resolution over transabdominal sonogram and gives 
better quality images in patients with high body mass index or with 
retroverted uterus. 
 
Rottem et al3 described the detection of fetal abnormalities in 
the first trimester using TVS in 1989. Similarly Quashie et al  in 
19924 investigated visualization of fetal anatomy with increasing 
gestation using Transvaginal Sonography. Braithwaite et al5 examined 
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fetal anatomy with both TAS and TVA between 12-13 weeks and 
concluded that the two scan modes were found to be complementary 
(1996). 
 
Gestation age at visualization of anatomical landmark. Chitty -
L, Pandya P. Prenatal Diag -19976
Gestation age in weeks 
S.No Landmarks 
TAS TVS 
1. Cranium 11,12-13 11-12 
2. Spine 12-13 11 
3. Long Bones 12-13 10-11 
4. Feet 12-13 13 
5. Four Chamber view 12-13 12 
6. Kidney 12-13 12 
7. Bladder 12-13 13 
8. Ant. Abd. Wall  12-13 12 
9. Face 12-13 12 
10. Stomach 13 11-12 
 
ULTRASOUND EXAMINATION AT 11-14 WEEKS 
 Viability 
 Determination of GA 
 Identification of multiple pregnancy and determining 
chorionicity. 
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 Screening for aneuploidy based on Nuchal translucency 
measurement. 
 Assessment of fetal gross anatomy. 
 
DETECTION OF VIABLE PREGNANCY 
Ultrasound examination at 11-14 weeks helps to diagnosis early 
pregnancy failure including missed abortion and anembryonic 
pregnancies.  
 
DETERMINATION OF GESTATIONAL AGE USING CRL 
Ultrasound helps in dating the pregnancy as the CRL up to 14 
weeks is the most accurate for determining the gestational age. When 
gestational age is confirmed the induction rate is reduced by about 
40%  
 
DETECTION OF  MULTIPLE PREGNANCY AND THE 
CHORIONICITY 
 
Ultrasound plays a major role in detecting the chorionicity in 
multiple pregnancy and the ideal time is 11-13 weeks scan. The 
Lambda sign which is due to chorionicity is a triangular tissue 
projection at the base of the intertwin  membrane Sepulveda W.et al 7. 
It is actually the extension of two chorion layers within the intertwin 
membrane that is present only in dichorionic pregnancy. 
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SCREENING FOR ANEUPLOIDIES  
Chromosomal Abnormalities occurs in approximately 0.9% of 
newborns and it is estimated that at least 10 to 15% of conceptions are 
chromosomally abnormal and about 95% of them are lost before term. 
Chromosomal abnormality can either be numeric or structural. 
Aneuploidy which refers to the presence of abnormal number of 
chromosomes is the most common clinically significant type of human 
chromosomal abnormality, and it occurs in 3% to 4% of recognized  
pregnancies. The risk of trisomy increases with maternal age and 
monosomy is seen less  frequently than trisomy. The most common 
aneuploidy at birth is Down’s syndrome (Trisomy 21)  
 
INCIDENCE 
Trisomy 21  -  1 in 700 live births 
Trisomy 18  -  1 in 8000 live births  
Trisomy 13  -   1in 20,000 live births  
Monosomy 45 x, Turner syndrome – 1 in 3000 live births  
Sonography plays a major role in detecting chromosomal 
abnormalises abnormality in 11 – 13 week by using  
1. Nuchal translucency 
2. Nasal bone Sonography 
3. Ductus venons Sonography   
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TRISOMY 21 / DOWN SYNDROME 
J.Langdon Down, in 18668 first made the observation of a 
subgroup of patients with particular facial features and mental 
handicap in the outpatients department of the London Hospital 
 
Lejeune and Jacobs et al,  in 1959, identified Trisomy 21 was 
the cause of Downs syndrome and the first chromosomal analysis 
from amniotic fluid was made in 1966. Antenatal screening for Down 
Syndrome was first performed in the 1970’s using advanced maternal 
age or as previous history of aneuploidy. In the 1980’s the association 
of Down syndrome with abnormal levels of certain specific serum 
markers were discovered and Triple Test came into role. 
 
The association between Downs syndrome and increased 
maternal age was noted in 1909 by Shuttle worth. In the past, invasive 
prenatal diagnosis for Downs syndrome with Amniocentesis and 
chorionic villous sampling was being offered only to women of 
advanced maternal age (older than 35 years of age at delivery) or 
those who previously had an affected child. Subsequently, invasive 
diagnosis was offered to women younger than 35 years of age who 
had abnormal second trimester multiple marker serum screening and 
also to those with abnormal second trimester sonographic sign, so 
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called soft markers of Down’s syndrome. But all the invasive prenatal 
diagnosis like amniocentesis and chorionic villous sampling had 
several limitation because it was associated with a risk of fetus         
loss of 1% 
 
Regarding the first observation made by J.L.Down in 18668 that 
the common characteristic of patients with trisomy 21 was poor skin 
elasticity, which gave the appearance that the skin was too large, it 
was realized in 1990’s that the excess skin could be visualized by 
Sonography as increased Nuchal translucency in the third month of 
intrauterine  life. 
 
Szabo and Gallen 9,10 the first to report the relationship between 
accumulated fetal nuchal fluid and fetal abnormalities. In 1992, 
Nicolaides et al introduced the new term Nuchal translucency which 
was defined as the thickness of translucent space between the skin and 
soft tissue over lying fetal spine, measured in millimeters and tenth of 
a millimeter  via ultrasound. Nicolaides et al (1992)11 had gained wide 
spread use of measurement of Nuchal translucency in conjunction 
with maternal serum markers in the detection of aneuploidy. 
 
Wapner and colleague (2003)12 detected 85% of case of Down’s 
syndrome with 9% false positive rate using Nuchal Translucency 
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measurement along with serum chorionic gonadotropin and pregnancy 
associated plasma protein A. Malone and colleagues (2003) 13 
reported a multicenter trial in 33,557 pregnant women who underwent 
first trimester and second trimester aneuploidy screening and 
concluded 85% of Down syndrome detected for 7.6% false positive 
rate. 
 
Nuchal Translucency  measurement at 11 - 13 weeks, combined 
with maternal age, provides an effective method of screening for 
trisomy 21. Pandya et al in 199515 concluded a detection rate of 75% 
for trisomy 21 when the cutoff rate of NT was >2.5 mm at 10-14 
weeks. Numerous studies have been done on NT measurement for 
detection of chromosomal abnormality. The largest study of this form 
of screening was performed by the Fetal Medicine foundation based in 
London14. The study was done in unselected patient and the overall 
detection rate for Down syndrome was 77 % for a 5% FPR. 
 
SURUSS Trial-Serum Urine And Routine Ultrasound Screening 
study detected 63% of Dows syndrome for 5% FPR. Similarly the 
BUN study and FASTER trial also revealed the strong relationship 
between increased Nuchal translucency and chromosomal 
abnormalities. 
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THE PATHOPHYSIOLOGY OF NT 
 
The etiology of increased Nuchal translucency is variable, but it 
is commonly believed to be due to fluid accumulation in the Nuchal 
region because of aortic isthmus narrowing or other fetal 
cardiovascular defects, abnormalities in the extracellular matrix or 
abnormal or delayed development of lymphatic system. 
 
Measurement of nuchal translucency 
  
 
Nuchal translucency can be measured successfully by abdominal 
ultrasound examination in about 95% of cases, in the others, it is 
necessary to perform Transvaginal Sonography. 
ULTRASONOGRAPHIC PICTURES 
   
 
 
 
 
 
 
Nuchal Translucency Measurement  
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                                    3D IMAGE OF NUCHAL FLUID 
 
                                                        
 
 
 
 
 
 
Criteria for MEASUREMENT 
 
 Strict saggital view appropriate  for Crown – rump length 
 The minimum crown – rump length should be 45 mm and the 
maximum 84 mm. 
 The optimum gestational age for measurement of fetal nuchal 
translucency is 11 to 13 + 6 weeks. 
 Neutral position of the fetus head. 
 Appropriate magnification (>70% image) 
 Away from amnion. 
 The maximum thickness of the subcutaneous translucency between 
the skin and the soft tissue overlying at cervical spine should be 
measured by placing the caliper on the inner borders of the above. 
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NEUTRAL POSITION OF FETUS AND MID SAGGITAL VIEW 
(11to 13.6wks scan) 
 More than one measurement must be taken and the maximum 
one should be recorded. Should be performed by trained 
sonographer as per Fetal Medicine Foundation guidelines. 
 
Based on various studies conducted in screening for aneuploidy  
using Nuchal translucency measurement the least cutoff value for 
predicting abnormalities is a NT measurement of > 3mm. 
 
Whenever a screening test in performed, the background risk is 
multiplied by the factor to calculate a new risk16. Therefore fetus with 
a given CRL, each NT measurement is a likelihood ratio that is 
multiplied by the background risk to provide a new risk. A woman’s 
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risk of having a fetus with trisomy 21 is higher if the NT measurement 
is large and lower if is small.  
 
NUCHAL TRANSLUCENCY SCREENING FOR OTHER 
ANEUPLOIDY.17,18,19,20 
 
Based on prenatal diagnosis and neonatal ascertainment the 
detection rate for trisomy 18 was 84%, Turner’s syndrome 80% and 
63% for Triploidy because the true prevalence of the condition in the 
first trimester in uncertain and most affected fetus spontaneously die 
in utero, true detection rate for these cases are difficult to calculate. 
INCREASED NT WITH NORMAL KARYOTYPE21
 
Souka and colleagues have studied that chromosomally normal 
fetus with increased NT > 3.5mm and concluded that 86% had no 
structural defects. If the NT thickness exceed 6.5mm then there in one 
in three chance that the pregnancy will end with a live birth of a 
infant with no major defects. 
 
INCREASED NT WITH OTHER MALFORMATIONS22
 
An abnormal NT with normal karyotype is mostly associated 
with cardiac abnormalities.23 Hence fetal echo is to performed at 16 
weeks and a second echo at 18 – 20 weeks. Diaphragmatic hernia is 
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associated with 37% of fetus with increased NT and this reflects 
venous congestion in the head and neck as a results of mediastinal 
shift or compression and impaired venous return.24 
 
Exomphalos is 10 times higher in fetus with normal karyotype 
and increased NT. Increased NT in twin gestation implies Twin to 
Twin transfusion syndrome. Enlarged Nuchal translucency and cystic 
hygroma in the first trimesters have an extremely high risk of fetal 
aneuploidy or other adverse pregnancy outcomes. Septated cystic 
hygroma are shown to have 50% chance of being associated with fetal 
aneuploidy, mostly trisomy 21.  
 
According to FASTER trial whenever a simple Nuchal 
translucency measurement of 3.00mm or greater is noted, CVS should 
be offered immediately because of a minimum risk of aneuploidy of 1 
in 6. 
 
NASAL BONE SONOGRAPHY IN THE FIRST TRIMESTER 
 
According to a study conducted by Ceciro et al, 25701, Fetuses  
with increased NT were also evaluated for the presence or absence of 
nasal bond during first trimester ultrasonography. The fetal nasal bone 
would not be visualized in 75% of Down Syndrome fetus. It was also 
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found that the absence of fetal nasal bone was not related to NT 
thickness and therefore the nasal bones screening has to be included 
in ultrasound screening modality with sensitivity of 85% with 1% 
FPR. 
 
DETECTION OF FETAL ANOMALIES 
 
The early pregnancy scan was initially introduced with the 
primary intention of measuring the CRL to achieve accurate dating. 
However, with improvement in the  resolution of the scan machine it 
is now possible to describe the normal anatomy of the fetus and to 
diagnose or suspect the presence of a wide range of fetal defects in 
the first trimesters of pregnancy.  
 
Protocol for first trimesters scan in a low risk population – 
Carol et al,  
 
ANATOMIC SURVEY 
CNS 
Obtain BPD view 
Normal Skull outline 
Presence of falx – cerebri 
2 choroid plexus 
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Face 
Profile, orbits and nose  
 
Neck 
Measure NT 
Heart 
FHR  
Four chamber view 
 
Thorax 
Location of stomach 
GIT 
Stomach  
Physiological hernia up to 11 weeks 5 days 
 
Bladder < 7MM 
Musculoskeletal system 
4 limbs, 2 hands and 2 feet 
 
 
CENTRAL NERVOUS SYSTEM DEFECTS 
 
In normal human fetuses, there is histological evidence that the 
onset of ossification of the cranial vault is at 10 weeks of gestation 
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and that, ultrasonographically by 11 weeks, there is hyperechogenicity 
of the skull in comparison to the underlying tissue. Ultrasound report 
have demonstrated that in the human there is progression from acrania 
to exencephaly and finally anencephaly. In the first trimester, the path 
gnomonic features is acrania, the brain being either entirely normal or 
at varying degrees of distortion and disruption. 
 
 
 
 
 
 
 
ENCEPHALOCELE 
 
 
 
 
 
                      
                                           ACRANIA 
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ACRANIA, ANENCEPHALY AND EXCENCEPHALY 
 
Schmidt and Kubli in 198226 demonstrated anencephaly at 13 
weeks. Rotten et al in 198927 reported a fetus at 9 weeks with an 
abnormal shape of the cephalic pole and cervical spine, and  at 11 
weeks, the diagnosis of anencephaly and open cervical spina bifida 
was made. 
 
In first trimester anencephalic fetus neural tissue can be seen 
but the cranium absent, giving rise to “Mickey Mouse” appearance, 
which is different from “Frog Eyes” seen in second trimesters. 
 
Kennedy et al (1990)28 described a case of acrania at 10 weeks 
in which the brain was of normal volume but appeared echogenic and 
disorganized, at 19 weeks the fragmented and degenerative brain was 
visualized. Bronshtein and Ornoy et al,29 reported a case with no 
abnormal findings at 9 and 13 weeks there was anencephaly at 14 
weeks. The findings from various screening studies clearly 
demonstrate that anencephaly can be reliably diagnosed at the routine 
11- 13 weeks scan, provided the sonographic features for this 
condition are specially searched for. 
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ENCEPHALOCELE 
This is a cranial defect with protrusion of meninges 
(Meningocele) and brain (Encephalocele). In about 75% of cases, the 
lesion is occipital but alternative sites include the frontoethmoidal and 
parietal region. It is often associated with microcephaly, 
hydrocephaly, spinabifida and meckel –gurber syndrome.  
 
 
Meckel - Gruber syndrome. 
 
 
Bronshtein and Zimmer (1991)30 described a case of occipital 
encephalocele that was seen as empty occipital sac at 13 weeks and 
later with brain tissue inside the sac at 14 weeks. Van Zalen – Sprock 
et al (1992)31 described a fetus at  11 weeks with two translucent 
areas in the occipital region.  
 
MECKEL – GRUBER SYNDROME 
USG Pictures 
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Meckel – Gruber syndrome, is a lethal autosomal recessive 
condition characterized by the triad of encephalocele, bilateral 
polycystic kidney and polydactyly. Pachi et al,32 described the 
sonographic features of this syndrome at 13 weeks gestation with 
occipital bony defects accompanied by encephalocele with enlarged 
kidneys. Similarly Sepulveda et al 33 and Van Zalen – Sprock et al, 
while examining  High risk pregnancies were able to correctly 
identify the Meckel –Gruber syndrome at 11-14 weeks scan. 
 
The diagnosis of this syndrome is easier at 11-14 weeks when 
the amniotic fluid is normal than during the second trimester when the 
presence of the associated oliogohydramnios could easily cause 
encephalocele and certain polydactyly to be missed. Additionally, at 
11-14 weeks, the fingers are easier to examine because they are 
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invariably extended, whereas in the second trimesters the hands are 
often clenched. 
 
HYDROCEPHALUS 
 
Congenital hydrocephalus with a prevalence of about 2 per 1000 
are most probably due to a combination of genetic and environmental 
factors. Antenatal sonographic diagnosis is based on the 
demonstration of dilated lateral cerebral ventricles. In normal fetuses, 
the outline of the lateral ventricles, the echogenic choroid plexus and 
the mid-line echo are visible by ultrasound from 9 weeks, at 10 – 11 
weeks, the third and fourth ventricles become visible and at 12 weeks, 
the cerebellum and thalamus can be seen. Ventriculomegaly usually 
develops after the 14th weeks of gestation. Hence the detection of 
hydrocephalus is mostly done in second trimester ultrasound. 
 
Lin et al (1992)34 reported a 12 week fetus with large head, 
small hemisphere and a fluid – filled intracranial cavity with no 
midline echo and was diagnosed to be a lethal sporadic condition 
called hydranencephally. 
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HOLOPROSENCEPHALY 
 
It is a spectrum of cerebral abnormalities resulting from 
incomplete cleavage of the fore brain. There are three types according 
to the degree of forebrain cleavage. The alobar type, which is most 
severe, is characterized by a monoventricular cavity and fusion of the 
thalami. In the semilobar type, there is partial segmentation of the 
ventricles and cerebral hemispheres posteriorly with incomplete 
fusion of the thalami. In lobar holoprosencephaly, there is normal 
separation of the ventricles and thalami but absence of the septum 
pellucidum. The first two type are often accompanied by facial 
abnormalities. 
 
Toth et al (1986)35 observed a floating membranous structure in 
place of skull at 11 weeks scan. Bronshtein and Wiener(1991)36 
described a case of alobar holoprosencephaly during routine 
ultrasound   at 14 weeks. 
 
Gonzalez - Gomez et al (1992)37 described a 10 weeks fetus with 
single ventricular cavity, absence of the orbits and mid-facial cleft. 
  
Snijders et al (1999) reported on the sonographic features of 46 
trisomy – 13 fetus at 10 – 14 weeks gestation. In 24% there was 
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holoprosencephaly and hence the most common related chromosomal 
abnormality was found to be trisomy -13. 
 
INIENCEPHALY 
 
This is a rare malformation of unknown etiology, characterized 
by cervical dysraphism and occipital (inion) defect with or without an 
encephalocele. 
 
Sherer et al (1996)38 reported the diagnosis of iniencephaly in a 
13 week fetus with acrania, persistently hyper extended head and 
spinal dysraphism. 
 
SPINA BIFIDA 
In Spina bifida, there is failure of closure of the neural tube, 
which normally occurs by the 6th week of gestation. In the spine of 
normal fetuses, there are three ossification centers, two pedicles and 
the spinal body and these are present from the 10th week gestation, 
allowing ultrasonographic visualization of the neural canal from this 
gestation. 
 
Braithwaite et al (1996) reported successful examination of the 
vertebra and overlying skin in both the transverse and coronal planes 
at 12-13 weeks of gestation. In 1980’s the main method of screening 
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for open spina bifida was by maternal serum α fetoprotein at around 
16 weeks of gestation and the method of diagnosis was amniocentesis 
and measurement of amniotic fluid α fetoprotein and 
acelylcholinesterase. Now the observation of scalloping of the frontal 
bones ( the lemon sign) and caudal displacement of the cerebellum       
(the banana sign) associated with spina bifida has led to the 
replacement of biochemical assessment with ultrasonography, both for 
screening and for diagnosis of this abnormality. 
 
Blumen field et al (1993)39, described the evaluation of the 
cranial and cerebellar sign of spina bifida that was scanned at 10,12 
and 15 weeks of gestation. Similarly Bernard and colleagues reported 
the diagnosis of spina bifida in a 12 weeds fetus with narrowing of the 
frontal bones and flattening of the occiput. However, the sonographic 
finding of spina bifida is difficult before 14 weeks as the prevalence 
of these signs at the 11-14 week scan remains to be determined. 
 
CARDIAC DEFECTS 
Abnormalities of the heart and great arteries are the most 
common congenital defects and the birth prevalence is 5 – 10 per 
1000. In general, about half of the cardiac defects are either lethal or 
require surgery and half are asymptomatic. The first two groups are 
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referred to as major defects and  specialist echocardiography are done 
at  around 20 weeks. Currently screening is based on examination of 
the four – chamber view at the 20 weeks scan and this  examination of 
the four chamber view of the heart can now be carried out at the 11 -
14 weeks scan. 
 
Braithwaite et al has proved that at 12 -13 weeks, the four – 
chamber view can be examined successfully  by TAS in 76% of the 
cases and by TVS in 95%.  
 
Dolkart and Reimers in 199140 reported that the earliest defined 
cardiac structures visible were the mitral and tricuspid valves 
followed by the aortic and pulmonary valves at 12 weeks. 
 
There are several case report of sonographic diagnosis of 
cardiac defects at 11 - 14 weeks of gestation. In, 1999, Hyett et al in a 
large population based cohort study detected that measurement of 
Nuchal translucency thickness at 11 – 14 weeks, constitutes the most 
effective method of screening for cardiac defects. In patients with 
increased Nuchal translucency it is now possible to undertake detailed 
cardiac scanning in early pregnancy. The prevalence of major cardiac 
defects increased with increased  NT thickness, from 5.4 per 100 with 
and NT measurement of 2.5 to 3.9mm to 233 per 1000 with an NT  
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measurement of greater than 5.5mm. The sensitivity of NT varies 
from  15% to 5.6% for the diagnosis of major cardiac defects.  
 
ABDOMINAL WALL DEFECTS  
Sonographically, the stomach is identified as a sonolucent cystic 
structure in the upper left quadrant of the abdomen. It is first 
visualized at 8-9 weeks and it is seen in all cases by 12 – 13 weeks. 
At 8 -10 weeks, all fetus demonstrate herniation of the midgut that is 
visualized as a hyperechogenic mass in the base of the umbilical cord 
and the retraction in to the abdominal cavity occurs at 10 -12 weeks 
and it is completed by 11 weeks and 5 days. 
 
EXOMPHALOS 
Prenatal diagnosis by ultrasound is based on the demonstration 
of the mid – line anterior abdominal wall defect, the herniated sac 
with its visceral contents and the umbilical cord insertion at the apex 
of the sac. Fetal exomphalos is associated with chromosomal defect, 
usually trisomy 18. Brown et al (1989) reported the diagnosis of 
exomphalos containing liver at 10 weeks. 
 
Van Zalen – Sprock et al (1997)41 reported the findings of 14 
cases with exomphalos diagnosed at 11 -14 weeks of gestation. In 
eight cases, there was increased Nuchal translucency thickness (3.5 – 
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10mm) and seven of these had chromosomal abnormalities, mainly 
trisomy – 18. The prevalence of exomphalos and the associated risk 
for chromosomal defects increases with maternal age and decreases 
with gestational age. 
 
GASTROSCHISIS42
Evisceration of the intestine which occurs through a small 
abdominal wall defect located just lateral and usually to the right of 
an intact umbilical cord. There is sparsity of reports on first trimester 
diagnosis. 
 
URINARY TRACT DEFECTS 
The fetal kidney and adrenals can first be visualized by TAS at 
9 weeks and they are seen in all cases from 12 weeks. The fetal 
bladder can be visualized in about 80% of fetuses at 11 weeks and in 
more than 90% by 13 weeks. AT 12 -13 weeks, the fetal kidneys can 
be  visualized in 99% of the cases. 
 
MEGACYSTIS 
Fetal megacystis is defined as a bladder with a longitudinal 
diameter of 7mm or more at 10 -14 weeks gestation. Bulic et al, 
(1987)43 demonstrated megacystis with oligohydramnios at 11 -14 
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weeks scan and the pathological examination after termination 
demonstrated urethral atresia’s, severe megacystis but normal kidney. 
 
Drugan et al (1989)44 reported a 12 week fetus with megacystis 
with normal kidneys and oligohydramnios and vesicoamniotic 
shunting was carried out and the pregnancy continued and delivered 
normally. In a recent study of 145 fetuses with megacystis, 25% had a  
 
 
 
 
 
                                     
 
 
MEGACYSTIS 
 
chromosomal abnormality, mainly trisomy 13 and 18 . In 75% of fetus 
with chromosomal abnormalities, NT thickness was also increased, 
possibly as a result of compression. The extent to which first 
trimesters diagnosis of megacystis and vesico – amniotic shunting 
could prevent the subsequent development of renal damage remains to 
be determined. 
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BILATERAL RENAL AGENESIS 
Bronshtein et al45, reported the prenatal diagnosis of bilateral 
renal agenesis at 14 weeks of gestation but it is usually diagnosed in 
the second trimester of pregnancy by the finding of a hydramnios, 
absence of urinary bladder and failure to identify the fetal kidneys. 
SKELETAL DEFECTS  
Limb buds are first seen by ultrasound at about the 8th week of 
gestation and the length of the humerus, radius/ulna, femur and 
tibia/fibula are similar at 11 -14 weeks46.  
 
Skeletal dysplasia are found in 1 in 4000 births. About 25% of 
the affected fetuses are still born and about 30% die in the neonatal 
period. The most common dysplasia are thanatotrophic dysplasia, 
osteogensis imperfecta and achondroplasia. Several cases reports have 
described skeletal defects in the first trimester of pregnancy and they 
are usually associated with increased Nuchal translucency. 
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MATERIAL AND METHODS 
 
The centre of study was at Department of Obstetric and 
Gynecology in Kilpauk Medical College. 
 
Study Design  : Prospective Study 
Period of Study  : April 2008 to December 2009 
 
Selection of Patients   
300 antenatal mothers who attended our Antenatal clinic at the 
outpatient department. 
 
INCLUSION CRITERIA 
Pregnant women at 11-13.6 weeks GA 
 H/o previous anomalies 
 H/o anomalies in the family  
 H/o diabetes 
 H/o Anticonvulsants medication 
 H/o. radiation  exposure 
 
EXCLUSION CRITERIA 
1. GA <11 Weeks 
2. GA >14 Weeks 
3. Multiple gestation  
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STUDY DESIGN 
Ultrasound screening was performed by experienced radiologist 
transabdominally  using 2 to 6MHZ curvilinear transducer and VITUS 
Ultrasound machine. Whenever visualization of fetal structure was 
suboptimal or a structural abnormality was suspected during 
transabdominal scan, transvaginal scan was always performed. 
 
Ultrasound screening was performed at 11-13.6 Weeks in all 
300 pregnant women. For those who had normal scans a follow up 
scan was done at 18-22 wks for confirmation. Fetal viability was 
examined and crown rump length was measured. 
 
Evaluation of fetal anatomy was done according to the 
following check list. 
1. Skull and brain 
2. Face (Facial Profile, Nasal Bone and orbits) 
3. Neck (Nuchal translucency measurement, presence of Cystic 
hygroma) 
4. Spine ( Examination of overlying skin and neural tube in 
longitudinal and transverse planes) 
5. Heart (Four chamber view, three vessel view, heart rhythm) 
6. Stomach ( Its existence in left upper abdomen) 
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7. Abdominal wall defect 
8. Kidney (existence, size, and shape) 
9. Urinary bladder (existence, size, and shape) 
10. Extremities (existence, size, and shape) 
 
Along with the evaluation of the anatomy, the Nuchal 
translucency measurement was done according to the guidelines 
established by the Fetal Medicine Foundation, in fetuses  with CRL 
between 45mm and 84mm at 11 to 13.6 weeks gestational age. 
 
The cut off value of NT measurement was taken as > 3 mm. 
When the NT measurement was > 3 mm it was considered to the 
abnormal and further confirmatory test was combined. The following 
confirmatory that were offered are, first trimester serum markers (free 
βhCG, PAPP-A), chorionic villous sampling, amniocentesis and triple 
screening or quadruple screening and it was left to the patients choice. 
Women were fully counselled before their ultrasound examination and 
written informed consent was obtained. Based on the anomalies 
detected, the patients were counselled regarding termination or 
continuation of pregnancy. All the patients were followed up till 
delivery. 
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Pregnancy outcome was obtained from our maternity unit or the 
patients themselves. The number of abnormalities that were detected 
at 11-13 weeks and at 20 weeks were analyzed. 
 
 
STATISTICAL ANALYSIS  
 
The test statistics used were chi-square, ‘t’ test and binary 
logistic regression.  
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RESULTS AND ANALYSIS 
 
During the one year period of 2008-2009. 300 pregnant women 
who attended our antenatal clinic were enrolled for  evaluation for 
fetal structural and chromosomal abnormalities between 11 and 13.6 
weeks of gestational ages. Out of the 300 antenatal mothers who had 
ultrasonogram, 16 patients were excluded from the study because 11 
patients were lost to follow up and not seen during the second 
trimester, 3 of them had findings suggestive of missed abortion at the 
time of the 11-13 weeks scan and 2 of them had miscarriages around 
16 weeks of gestation.  
 
The remaining 284 antenatal mothers, underwent the second 
trimester scan and were analysed based on the distribution of age, 
gravida, risk factors, no of anomalies detected and the outcome of 
their pregnancies.  
 
Mean Age In The Study Group  
Study group No Mean Std. deviation 
Normal  275 24.1418 3.98147 
Anomalies 9 23.5556 2.12786 
P= 0.661 
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The mean age of the participants was 24 yrs among the normal 
pregnancies and 23 yrs among the anomalous pregnancies  
Mean Gestational Age: 
Total  Mean (wks)  Std. deviation 
284 12.4 days  0.66102 
   The mean examination time of the early scan was 12wks 
and 4 days  
 
Mean CRL in cm  
 
Total  Mean (cm)  Std. deviation 
284 6.1  3.60364 
 
 
The mean crown rump length measurement during the 11-13.6 
wks scan was 6.1cm.  
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AGE GROUP DISTRIBUTION 
Table :1 
  Age group  Normal Anomalies Total 
< 20 yrs 49 17.3% 
1 
0.4% 
50 
17.6% 
21-25yrs. 145 51.1% 
5 
51.1% 
150 
52.8% 
26-30yrs 62 21.8% 
3 
1.1% 
65 
22.9% 
>30yrs 19 6.7% 
0 
. 
19 
6.7% 
Total 
275 
96.8% 
9 
3.2% 
284 
100% 
 
P= 0.729 not significant 
 
Most of the antenatal mothers  in the study group was in the age 
group of 21-25yrs. (52.8%). 
 
Among the anomalies detected, about 5of them were between 
21-25yrs of age (55.6%). 
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GRAVIDA DISTRIBUTION 
Table :2 
Gravida No. of Normal No. of Anomalies Total 
Primi 128 45% 
6 
2.1% 
134 
47.2% 
Multi 147 51.8% 
3 
1.1% 
150 
52.8% 
Total 275 96.8% 
9 
3.2% 
284 
100% 
 
P=0.234 not significant  
z 
Primigradvida accounted for 47.2% in the study group and 
multigravida were 52.8%. The anomalies were more among the primi 
gravida. 
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PREVIOUS OBSTETRIC HISTORY AMONG MULTIGRAVIDA 
 
Table :3 
 
Previous obstetric 
outcome 
No. of 
normal No. of anomalies Total 
Normal 91 0 91 
Poor obstetric out 
come  56 3 59 
Total 147 3 150 
 
P=0.109 not significant  
 
Among the multigravida 59 antenatal mothers had poor obstetric 
outcome. The mothers of the three anomalous fetuses had previous 
poor obstetric outcome. 
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CONSANGUINITY  
Table :4 
 
Consanguinity Normal Anomalies Total 
NCM 231 6 237 (83.5%) 
IIº CM 16 1 17 (6.0%) 
IIIº CM 28 2 30 (10.6%) 
Total  275 9 284 (100%) 
 
P=0.383 not significant  
 
237 (83.5%) antenatal mothers had non-consanguineous  
marriage 17 (6.0%) had second degree consanguineous marriage and 
30 (10.6%) had third degree consanguineous marriage. Among the 9 
antenatal mothers with anomalous fetuses 6 (66.7%) were NCM, one 
(11.1%) was of second degree and 2 (22.2%) were of third degree 
consanguinity.  
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PREVIOUS H/O ANOMALY 
 
Table :5 
 
 
Study group Normal Anomalies Total 
H/o previous 
anomalies 
6 1 7  (2.5%) 
No H/o previous 
anomalies  
269 8 277 (97.5%) 
Total  275 9 284  (100%) 
P= 0.204 not significant  
 
Among the nine anomalies detected only one was a recurrent 
anomaly .  
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FAMILY H/O ANOMALY 
 
 
Table :6 
 
Study group Normal Anomalies Total 
Family H/o anomalies 1 1 2  (0.7%) 
Others  274 8 282 (99.3%) 
 
 
P=0.000 significant  
 
 
Of the 9 anomalies there was family History of similar anomaly 
in one  fetus  
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H/O DRUG INTAKE 
 
Table: 7 
 
 
 
 
 
 
  
Study group Normal Anomalies Total 
H/o drug intake 4 2 6 (2.1%) 
Others 271 7 278 (97.9%) 
 
P=0.000 significant  
 
 
of the 9 anomalies two of the mother gave a history of drug . in 
take in the first trimester and carried fetuses with cleft lip and cleft 
palate and the other had an anencephalic fetus. The particular drug 
was not known in the case of cleft lip. The patient with anencephaly 
baby had H/o antiepileptic drug intake.  
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H/O MEDICAL DISORDER 
 
Table: 8 
 
 
Medical disorder Normal Anomalies 
Overt diabetes  5 0 
Heart disease  4 0 
Epilepsy  3 1 
GDM 8 0 
 
Mothers with out 
medical disorders  
255 8 
P= 0.053 not significant  
There was one anomalous fetus among the patients with  
epileptic  disorder who  was on anticonvulsant drug. 
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PREGNANCY OUTCOME 
Table: 9 
 
Pregnancy outcome Normal Anomalies Total 
Alive 271 1 272 (95.8%) 
IUD 4 0 4 (1.4%) 
TOP 0 7 7 (2.5%) 
NND 0 1 1 (0.4%) 
 
 
272 (95.8%) of the antenatal mothers had delivered alive baby 
4(1.4%) had intrauterine fetal death due to medical complication in 
pregnancy  Termination of pregnancies was done in 7 (2.5%) cases 
with anomalous fetuses and one anomalous baby that was born alive 
went in for early neonatal death. (0.4%).(it was a cases of  
meningomyelocele and the mother refused termination of pregnancy) 
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MODE OF DELIVERY 
Table: 10 
 
 
 Mode of termination of the anomalous fetuses  
Mode of Termination  Anomolous fetuses  
I st Trimester MTP 3 
IInd Trimester MTP 3 
Hysterotomy 1 
Normal vaginal delivery  2 
 
7 Mothers with anomalous fetuses underwent medical 
termination of pregnancy and in  one of the case, it went for 
Hysterotomy   
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TOTAL NO OF ANOMALIES DETECTED  IN THE STUDY 
GROUP 
 
Table: 11 
 
Study group Frequency (n) Percentage 
Normal  275 96.8% 
Anomalies  9 3.2% 
Total  284 100% 
    
 
There were 9 fetuses with anomalies in the study population 
(3.2%) and all were detected by ultrasound screening of the total 9 
(3.2%) anomalous fetuses, 3 (1.1%) were detected at 11-13 weeks 
scan and the remaining 6 anomalous fetuses were detected during the 
followup second trimester scan.  
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FIRST TRIMESTER SCAN ANOMALIES 
 
Table: 12 
 
Study Group Frequency (n) Percentage 
Normal  281 98.9% 
Anomaly  3 1.1% 
Total  284 100% 
    
The sensitivity  of the 11-13 wks scan in detecting the 
anomalies was about 33.33%.  The overall sensitivity in  detecting the 
anomalies using ultrasound in the study population was about 100%.  
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                     FIRST TRIMESTER SCAN ANOMALIES 
 
 
 
 
 
ANENCEPHALY :1 
 
 
 
 
 
 
                                   ANENCEPHALY :2 
 
 
 
 
 
                         
CYSTIC HYGROMA 
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NUCHAL TRANSLUCENCY MEASUREMENT 
 
 
Abnormal nuchal translucency measurement ie > 3mm was 
noted in 2 of the 284 cases (0.7%). Only one case with abnormal NT 
was found to be an anomalous fetus  
 
Case I.  
 
The NT measurement was about 3.07 mm and the patient 
underwent chorionic villous sampling after counseling. The karyotype 
report was found to be normal and she was followed up regularly and 
there was no abnormalities detected in the second scan. The patient 
delivered an alive normal baby.  
 
Case II 
 
The NT measurement was about 11.2mm but was diagnosed to 
be a case of cystic hygroma with septation . The patient was 
counselled for chorionic villous sampling to detect chromosomal 
abnormalities but the patient refused and opted for termination of 
pregnancy.  
2).doc 
64
ABNORMAL NT SCANS CASE 1 
 
 
 
  
   
 
 
NT=11.2 mm (Cystichygroma)  CASE 2 
 
 
 
 
 
 
 
NT=3.07mm 
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CYTOGENETIC ANALYSIS 
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TYPES OF ANOMALIES DETECTED AT THE 11-13 WK SCAN 
 
S.No. Anomalies GA(wks) Outcome 
1. Cystic hygroma  13 TOP 
2. Anencephaly  13.2 TOP 
3. Anencephaly 12.2 TOP 
 
Cranial abnormalities was the most common abnormality 
detected in the first trimester and all of them were terminated.  
TYPES OF ANOMALIES DETECTED AT THE 18-22 WKS 
SCAN 
S.No. Anomalies Outcome 
1. Hydrocephalus TOP 
2. Hydrocephalus TOP 
3. Occipital meningocele TOP 
4. Meningomyelocele NND 
5. Cleft lip and cleft palate Alive 
6. Skeletal dysplasia 
(achondroplasia) 
TOP 
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ACHONDROPLASIA USG PICTURE 
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CLEF LIP AND CLEFT PALATE 
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HYDROCEPHLUS 
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MENINGOMYELOCELE 
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OCCIPITAL ENCEPHALOCELE 
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Total no. of 6 anomalous fetuses which were not detected in the 
11-13 wks scan were detected in the 18-22wks scan. Four cases were 
terminated. The anomalous baby with deft lip and deft palate was 
delivered alive and was referred to pediatric surgery department. 
The mother who refused TOP delivered a baby with 
meningmyelocele which was born alive but went in for early neonatal 
death due to sepsis.  
NICU ADMISSION 
Study group Normal Anomalies Total 
NICU Admission  42 2 44 
Others  229 0 229 
Total  271 2 273 
44 (16.1%) babies were admitted in NICU.  
 
Both the anomalous babies with cleftlip and cleft palate and 
meningomyelocele were admitted into the NICU 
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BINARY LOGISTIC REGRESSION WAS USED TO IDENTITY 
THE ASSOCIATED RISK FACTORS WITH RESPECT TO 
TOTAL ANOMALIES 
DEPENDENT VARIABLE: TOTAL ANOMALIES 
INDEPENDENT VARIABLES : 1. FAMILY H/0 ANOMALJES  
2. H/O DRUG INTAKE  
VARIABLE NAME  CHI-SQUARE  P VALUE  
FAMILY H/O. OF ANOMALIES  5.983 0.014 
H/O DRUG INTAKE  10.946 0.001 
 
It was found that  family H/O anomalies and positive history of 
drug intake (anticonvulsants and other teratogenic drugs) had a very 
high risk for presence  of anomalies. Hence first trimester ultrasound 
is useful in early diagnosis of structural anomalies.  
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DISCUSSION 
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DISCUSSION 
 
The incidence of major fetal anomalies in this study was about 
3.2% and it falls within the range reported in the literature 47,48.  
 
In this study detailed examination of fetal structures at 11-13.6 
wks of pregnancy revealed 33.3% of major structural abnormalities in 
low risk pregnant women. This result is similar to the results reported 
from other studies.  
 
Hernadi and Torocsik in 199749 reported first trimester 
detection rate of 36% of structural anomalies in low risk Population. 
 
Carvalho et al., (2002),51  reported about 38% of structural 
anomalies detectable in first trimester.  
 
Taipale et al., (2004), 52  had reported a low detection rate of 
about 18% in first trimester and it was mainly due to poor training and 
limited examination time.          
 
Souka et al., (2006)54 and Dane et al (2007) had reported high 
detection  rate of about 50% and 70% respectively. This high 
detection rate of structural abnormalities at 11-13.6 wks of gestation, 
reflects the fact that experienced obstetrician or radiologist has a 
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major role and  good training is mandatory with high resolution 
ultrasound machine  
 
Studies Examining The Sensitivity of First and Second Trimester 
Ultrasound In Detecting Major Fetal Structural Defects 
 
 
Authors N Population Method Major  anomalies 
First 
trimester 
detection  
rate 
Total 
detect
ion 
rate 
Hernadi  
and Torocsik 
3991 Low risk TA 35 (0.9%) 36% 72% 
Carvalho et al 2853 Low risk TA+TV 66(2.3%) 38% 79% 
Taipale et al  4513 Low risk TV 33(0.7%) 18% 48% 
Souka et al 1148 Low risk TA+TV 14(1.2%) 50% 92% 
Chen et al  1609 High risk TS+TV 26(1.6%) 54% 77% 
Economdies and 
Braithwaite  1632 Low risk TA+TV 13(0.8%) 54% 77% 
 
Increased Nuchal translucency is known to be associated with 
chromosomal defects and major structural abnormalities, in particular 
cardiac anomalies and genetic syndrome. In our study the abnormal 
Nuchal translucency measurement was noted in 2 cases (0.7%) and 
both were found to be false positive cases.  This is mainly attributed 
to the small sample size taken in the study and most of them were 
among the low risk population.  
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The introduction of routine first trimester scanning will have 
important implication for second trimester scan.  Most of the 
chromosomal abnormality are detected in the first trimester scan (11 – 
13 weeks) using nuchal translucency thickness and hence it is used for 
screening for Downs syndrome and other abnormalities.  Once it is 
found to be screen positive, the confirmative test such as chorionic 
villous sampling, and amniocentesis are done. 
 
The chorionic villous sampling done at 11 to 13 weeks of 
gestation helps in earlier diagnosis of aneuploidy and early 
amniocentesis is no longer optimal at 11 – 13 weeks because of its 
higher association for fetal loss, fetal club foot, and procedure failure.  
Previously the cell culture and karyotype results took 2 to 3 weeks.  
But now the FISH technique helps in providing the karyotype results 
within 48 hrs. 
 
Hence early detection of fetal malformation allows early 
termination of malformed fetuses.  Once an abnormality is diagnosed, 
parents will choose for elective termination.  Prenatal diagnosis not 
only allows termination but also has profound implication on 
antenatal and intrapartum management such as in utero treatment of 
diaphragmatic hernia and other fetal therapies. 
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SUMMARY  
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SUMMARY 
This study was chosen to detect the incidence of major fetal 
abnormalities in general obstetric population and to evaluate the 
performance of ultrasonogram screening during 11 to 13 weeks 
gestation. 284 antenatal mother were screened for fetal anomalies in a 
two stage ultrasound scanning at 11 to 13 weeks gestation and follow 
up scan at 18 -22 weeks. 
• The incidence of major fetal abnormalities was 3.2%. 
• The sensitivity of first trimester (11-13 wks ) scan in detecting 
the anomalies was 33% in this study. 
• The overall sensitivity of ultrasonogram in detecting the 
anomalies was 100%. 
• Increased nuchal translucency measurement was detected in two 
cases.  
• 3 cases of missed abortion was detected at the time of 11-13 
weeks scan which was an incidental finding.  
• Craniospinal abnormalites were the most common abnormalities 
detected and hence it indicates the need for periconceptional 
folic acid intake.  
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CONCLUSION 
 
1. The detection of the major anomalies at this early gestation (11-13 
wks) offers to the parents the option of an earlier, safer and 
psychologically less traumatic termination of the pregnancy.  
 
2. The ultrasound examination at 11-14 wks to screen for fetal 
abnormalities is effective and can be an adjunct to the routine 18-22 
weeks anomaly scan.   
 
3. Hence first trimester ultrasound (11-13wks) must be made mandatory, 
not only for the detection of major fetal anomalies, but also for 
diagnosing multiple pregnancy and abnormal pregnancy like missed 
abortion , molar pregnancy and ectopic pregnancy.  
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THE VALUE OF 11-13 WKS SCAN – IN 
SCREENING FOR FETAL ANOMALIES 
PROFORMA 
1. Patient’s Name     : 
2. Age       : 
3. Husband’s Age    : 
4. Obsteteric code     : 
5. No.of children with sex   : 
6. Marital Status and consanguinity  : 
7. LMP      : 
8. Weeks of pregnancy    : 
9. H/O Genetic /Medical Disease in family: 
10. High risk Factor : 
a) H/O Previous anomalies   : 
b) H/O DM (overt / GDM )  : 
c) H/O congenital Heart disease  : 
d) H/O epilepsy    : 
e) H/O drug intake    : 
11. USG (11-13.6 wks scan)   : 
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a. CRL      : 
b. GA     : 
c. Nuchal Translucency   :  
d. Skull      : 
e. Abdominal wall    : 
f. Bladder      : 
g. Extremities     : 
h. Other      : 
12. Bio –Chemical /Cyto – Genetic  : 
13. Second trimester USG   : 
14. Pregnancy Outcome    : 
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1 27 Multi n Ncm N N Y N 13 6.6 1.1 Normal Normal Normal Alive VD N N
2 21 Primi - Ncm N N N N 12 65 1.2 Normal Normal Normal Alive VD N N
3 22 Primi - Ncm N N N N 13 6.45 1.5 Normal Normal Normal Alive CS N N
4 20 Multi n Ncm N N N N 13 6.4 1.8 Normal Normal Normal Alive VD N N
5 26 Primi - Ncm N N N N 13 6.6 1.9 Normal Normal Normal Alive CS N N
6 22 Multi n Ncm N N N N 12 5.3 1.2 Normal Normal Normal Alive VD N N
7 34 Multi n Ncm N N N N 11.4 4.6 0.9 Normal Normal Normal Alive CS N N
8 25 Multi n 3˚cm N N N N 13 6.4 1.9 Normal Normal Normal Alive VD N N
9 26 Primi - Ncm N N N N 12.3 5.8 1.8 Normal Normal Normal Alive VD LBW Y
10 22 Multi poor Ncm N N N N 13 6.5 1.5 Normal Normal Normal Alive VD N N
11 31 Multi n Ncm N N N N 13 6.4 1.8 Normal Normal Normal Alive VD N N
12 22 Primi - 3˚cm N N N N 13 6.6 1.2 Normal Normal Normal Alive VD N N
13 22 Multi n 3˚cm N N N N 12 5.3 1 Normal Normal Normal Alive VD N N
14 24 Primi - Ncm N N N N 12.2 5.6 1.1 Normal Normal Normal Alive VD N N
15 23 Multi poor Ncm Y N N N 12.4 5.9 1 Normal Normal Normal Alive VD LBW Y
16 20 Primi - Ncm N N N N 11.6 4.9 1.5 Normal Normal Normal Alive VD N N
17 29 Multi n Ncm N N N N 13 6.4 1.9 Normal Normal Normal Alive VD N N
18 22 Multi n Ncm 0 N N N 13 6.5 1 Normal Normal Normal Alive VD N N
19 26 Multi n Ncm N N N N 12 5.3 1 Normal Normal Normal Alive VD N N
20 27 Primi - Ncm N N N N 12 5.3 1 Normal Normal Normal Alive CS N N
21 22 Multi n Ncm N N N N 13 6.6 1 Normal Normal Normal Alive VD N N
22 21 Primi - Ncm N N N N 11.6 4.6 0.9 Normal Normal Normal Alive VD N N
23 22 Multi n 3˚cm N Y N N 11 4.5 0.9 Normal Normal Normal Alive VD N N
24 23 Multi n Ncm N N N N 13 6.7 1.1 Normal Normal Normal Alive VD N N
25 25 Multi poor Ncm N N N N 12 5.3 1 Normal Normal Normal Alive CS N N
26 32 Multi poor Ncm N N N N 11 4.6 0.5 Normal Normal Normal Alive VD N N
27 23 Primi - Ncm N N N N 12.2 5.6 0.9 Normal Normal Normal Alive VD N N
28 18 Primi - Ncm N N N N 12.4 5.6 0.9 Normal Normal Normal Alive VD N N
29 25 Multi poor Ncm N N N N 12.3 5.7 1 Normal Normal Normal Alive VD N N
30 23 Multi poor Ncm Y N N N 12 5.8 1.1 Normal Normal Normal Alive VD N N
MASTER CHART
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31 19 Primi - Ncm N N N N 12 5.6 1 Normal Normal Normal Alive CS N Y
32 28 Primi - Ncm N N N N 12.4 5.6 1 Normal Normal Normal Alive For N N
33 29 Primi - Ncm N N N N 11 4.5 1.2 Normal Normal Normal Alive VD N N
34 21 Primi - Ncm N N N N 11.2 5.4 1.1 Normal Normal Normal Alive VD N N
35 29 Primi - Ncm N N N N 12 5.4 0.9 Normal Normal Normal Alive VD LBW Y
36 21 Multi n Ncm N N N N 13 6.4 1.1 Normal Normal Normal Alive VD LBW Y
37 25 Primi - Ncm N N N N 11.6 4.8 1.2 Normal Normal Normal Alive VD N N
38 24 Multi n Ncm N N N N 12.3 5.7 1 Normal Normal Normal Alive CS N N
39 23 Multi n 3˚cm N N N N 11.6 5 1 Normal Normal Normal Alive VD N N
40 22 Primi - Ncm N N N N 12 5.3 1.2 Normal Normal Normal Alive VD N N
41 22 Multi 2 Ncm N N N N 12.4 5.8 1.2 Normal Normal Normal Alive VD N N
42 29 Primi - Ncm N N N N 13 6.4 1.5 Normal Normal Normal Alive VD N N
43 20 Primi - Ncm N N N N 11.3 4.1 1.1 Normal Normal Normal Alive CS N N
44 35 Multi n 3˚cm N N N N 12 5.1 0.9 Normal Normal Normal Alive CS N N
45 28 Primi n Ncm N N N N 12.4 5.9 0.9 Normal Normal Normal Alive VD N N
46 20 primi - Ncm N N N N 13.2 6.6 1.2 Normal Normal Normal Alive VD N N
47 28 Primi n Ncm N N N N 13.1 6.6 1.1 Normal Normal Normal Alive CS N N
48 21 Multi - Ncm N N N N 12.1 5.3 1 Normal Normal Normal Alive VD N N
49 30 Primi n Ncm N N N N 11.6 5 0.8 Normal Normal Normal Alive VD N N
50 26 Multi poor Ncm N N N N 11.3 4.5 0.9 Normal Normal Normal Alive VD LBW N
51 22 Multi - Ncm N N N N 13.1 6.4 0.5 Normal Normal Normal Alive For N N
52 25 Primi - Ncm N N N HD 13.1 6.6 0.9 Normal Normal Normal Alive VD LBW N
53 29 Primi - Ncm N N N N 11.6 5 1.2 Normal Normal Normal Alive VD LBW N
54 21 Primi n Ncm N N N N 13.5 7.4 1.1 Normal Normal Normal Alive VD N N
55 27 Multi poor Ncm N N N N 13.5 7.4 1.1 Normal Normal Normal Alive CS N N
56 22 Primi - 3˚cm N N N N 13.4 7.2 1.2 Normal Normal Normal Alive VD N N
57 21 Primi - 2˚cm N N N N 12.1 5.3 1.4 Normal Normal Normal Alive VD N N
58 20 Primi - Ncm N N N N 12.5 6.1 1.5 Normal Normal Normal Alive VD N N
59 20 Multi poor 2˚cm N N N N 12.6 6.3 1 Normal Normal Normal Alive VD N N
60 19 Primi - Ncm N N N N 11.5 4.8 1.5 Normal Normal Normal Alive VD N N
61 22 Primi - Ncm N N N N 12.2 5.6 0.8 Normal Normal Normal Alive CS N N
62 21 Primi - Ncm N N N N 12.6 6.2 0.9 Normal Normal Normal Alive VD LBW Y
63 28 Primi - Ncm N N N N 11.4 4.7 0.9 Normal Normal Normal Alive VD LBW Y
64 19 Primi - Ncm N N N N 12 5.3 1.1 Normal Normal Normal Alive VD N N
65 22 Primi - Ncm N N N DM 13.4 7.2 1.3 Normal Normal Normal Alive CS N Y
66 26 Multi poor 2˚cm N Y N N 11.4 4.6 1.2 Normal Abnormal occipital encephalocele TOP Hys - -
67 27 Primi - Ncm N N N N 12.5 6.1 1 Normal Normal Normal Alive VD N N
68 19 Primi - Ncm N N N N 13.5 7.4 1.2 Normal Normal Normal Alive VD N N
69 20 Primi - Ncm N N N N 12 5.3 1.1 Normal Normal Normal Alive VD N N
70 19 Primi - Ncm N N N N 13.1 6.5 1.2 Normal Normal Normal Alive VD N N
71 22 Primi - Ncm N N N N 11.6 5 0.8 Normal Normal Normal Alive VD N N
72 22 Multi n Ncm N N N N 12.3 5.7 1.5 Normal Normal Normal Alive CS N N
73 22 Primi - Ncm N N N N 13 6.4 1.2 Normal Normal Normal Alive VD N N
74 26 Primi - Ncm N N N N 13 6.8 11.2 Ab normal Normal cystichygroma TOP MTP1
75 21 Primi - Ncm N N N N 12 5.3 0.8 Normal Normal Normal Alive CS LBW Y
76 23 Multi n Ncm N N N N 11.3 4.5 0.9 Normal Normal Normal Alive CS N N
77 20 Primi - Ncm N N N N 12 5.3 0.9 Normal Normal Normal Alive VD N N
78 21 Primi - Ncm N N N N 12.5 6.1 1.2 Normal Normal Normal Alive VD N N
79 20 Primi - Ncm N N N N 13.4 7.2 1.4 Normal Normal Normal Alive VD N N
80 22 Primi - 3˚cm N N N N 13.2 6.9 1 Normal Normal Normal Alive VD N N
81 22 Multi n Ncm N N N N 13.1 6.6 1.1 Normal Normal Normal Alive CS N N
82 20 Primi - Ncm N N N N 12.6 6.2 1 Normal Normal Normal Alive VD N N
83 23 Multi poor Ncm N N N N 12.4 5.9 0.9 Normal Normal Normal Alive CS N N
84 21 Multi n Ncm N N N N 12.1 5.3 1.2 Normal Normal Normal Alive VD N N
85 21 Primi - Ncm N N N N 13.4 7.2 1.3 Normal Normal Normal Alive CS N N
86 20 Multi n Ncm N N N N 12.2 5.5 1.1 Normal Normal Normal Alive VD N N
87 22 Primi - Ncm N N N N 13 6.4 1.5 Normal Normal Normal Alive VD N N
88 24 Multi poor Ncm N N N N 12.5 6.1 1 Normal Normal Normal Alive for N N
89 22 Multi poor Ncm N N N N 11.6 5 0.9 Normal Normal Normal Alive CS N N
90 22 Primi - Ncm N N N N 11.4 4.7 0.8 Normal Normal Normal Alive CS N N
91 27 Primi - Ncm N N N DM 11.4 4.8 0.8 Normal Normal Normal Alive CS N N
92 26 Multi n Ncm N N N N 12.5 6.1 1 Normal Normal Normal Alive VD N N
93 28 Multi n Ncm N N N N 12.6 6.3 1.2 Normal Normal Normal Alive VD N N
94 24 Multi n ncm N N N N 13.2 6.2 1.3 Normal Normal Normal Alive CS N N
95 22 Primi - Ncm N N N DM 13.6 7.6 1.5 Normal Normal Normal Alive VD LBW Y
96 28 Multi poor 3˚cm Y N Y EPI 13.5 7.6 1.1 Normal Normal Normal Alive CS N N
97 20 Multi n Ncm N N N N 13.6 7.6 1.5 Normal Normal Normal Alive CS LBW Y
98 24 Primi - Ncm N N N N 12.4 5.9 1 Normal Normal Normal Alive VD LBW Y
99 21 Primi - 2˚cm N N N N 13.4 7.3 1.3 Normal Normal Normal Alive VD N N
100 25 Multi n 2˚cm N N N N 12 5.3 1.2 Normal Normal Normal Alive VD N N
101 28 Primi - Ncm N N N N 11.5 4.8 0.7 Normal Normal Normal Alive VD LBW Y
102 31 Multi n Ncm N N N N 12.5 6.2 1 Normal Normal Normal Alive VD N N
103 24 Multi n Ncm N N N N 11.6 5 1 Normal Normal Normal Alive VD N N
104 23 Primi - Ncm N N N N 12.6 6.3 1.2 Normal Normal Normal Alive VD N N
105 22 Primi - Ncm N N Y EPI 13.5 7.4 1.6 Normal Normal Normal Alive VD N N
106 22 Multi n Ncm N N N N 13.1 6.6 1.2 Normal Normal Normal Alive CS N N
107 22 Primi - Ncm N N N N 13.4 7.2 1.5 Normal Normal Normal Alive VD N N
108 26 Multi poor 3˚cm N Y N N 12.4 5.9 1.2 Normal Abnormal skeletal dysplasia TOP MTP2 - -
109 24 Multi n 3˚cm N N N N 13.5 7.4 1.2 Normal Normal Normal Alive VD N N
110 23 Primi - Ncm N N N GDM 13.1 6.6 1.2 Normal Normal Normal Alive VD LBW Y
111 20 Primi - Ncm N N N N 12.5 6.1 1.3 Normal Normal Normal Alive CS N N
112 25 Multi n Ncm N N N N 12.2 5.5 1.6 Normal Normal Normal Alive VD N N
113 26 Multi n Ncm N N N N 12.1 5.3 1.2 Normal Normal Normal Alive CS N N
114 25 Multi n Ncm N N N N 13.1 6.6 1.5 Normal Normal Normal Alive VD N N
115 29 Multi n Ncm N N N HD 12.2 5.5 1 Normal Normal Normal Alive For N N
116 25 Primi - Ncm N N N N 13.1 6.7 1.2 Normal Normal Normal Alive CS N N
117 24 Primi - Ncm N N N N 11.6 5 0.9 Normal Normal Normal Alive VD N N
118 25 Primi - Ncm N N N N 12.4 5.9 1.9 Normal Normal Normal Alive VD N N
119 26 Primi - Ncm N N N N 13.6 7.6 1.3 Normal Normal Normal Alive VD N N
120 30 Multi poor Ncm N N N N 12 6.4 1 Normal Normal Normal Alive CS N N
121 24 Multi n Ncm N N N N 12.6 6.3 1.1 Normal Normal Normal Alive VD N N
122 22 Multi n 2˚cm N N N N 12.4 5.4 1.2 Normal Normal Normal Alive VD N N
123 24 Primi - Ncm N N N N 12.1 5.8 1.2 Normal Normal Normal Alive VD N N
124 20 Primi - Ncm N N N N 12 5.3 0.9 Normal Normal Normal Alive VD N N
125 25 Primi - Ncm N N N N 13 6.4 1.5 Normal Normal Normal Alive VD N N
126 33 Multi poor Ncm N N N N 12.2 5.6 1.7 Normal Normal Normal Alive CS LBW Y
127 32 Multi poor Ncm N N N GDM 13.6 7.6 1.4 Normal Normal Normal Alive CS N N
128 22 Multi n Ncm N N N N 13.1 6.6 1.1 Normal Normal Normal Alive VD N N
129 24 Primi - Ncm N N N N 12.1 5.3 1.1 Normal Normal Normal Alive VD N N
130 19 Multi poor Ncm N N N N 12 5.3 1 Normal Normal Normal Alive VD LBW N
131 28 Multi n Ncm N N N N 11.6 5 0.9 Normal Normal Normal Alive VD N N
132 24 Primi - Ncm N N Y EPI 12.2 5.5 1.9 Ab normal Normal Anencephaly TOP MTP1
133 30 Multi n Ncm N N N N 12.1 5.3 1 Normal Normal Normal Alive VD N N
134 23 Multi n Ncm N N N N 13 6.4 1 Normal Normal Normal Alive VD N N
135 25 Multi n Ncm N N N N 12.6 6.3 1.2 Normal Normal Normal Alive VD N N
136 23 Primi - 3˚cm N N N N 12 5.2 0.9 Normal Abnormal Hydrocephalus TOP MTP2 N N
137 29 Multi poor Ncm N N N N 11.4 4.7 0.5 Normal Normal Normal Alive VD N N
138 26 Multi poor Ncm N N N N 11.4 4.7 0.8 Normal Normal Normal Alive VD N N
139 28 Multi n Ncm N N N N 12 5.3 1.2 Normal Normal Normal Alive VD N N
140 25 Primi - Ncm N N N N 11.6 5 0.8 Normal Normal Normal Alive VD N N
141 23 Primi - Ncm N N N N 12 5.3 1 Normal Normal Normal Alive VD N N
142 34 Multi n Ncm N N N N 13 6.4 1.2 Normal Normal Normal Alive VD N N
143 25 Multi n 2˚cm N N N N 12.4 5.9 1.1 Normal Normal Normal Alive VD N N
144 27 Multi poor 2˚cm N N N N 13 6.4 1.1 Normal Normal Normal Alive CS N N
145 30 Primi - Ncm N N N N 12.5 6.1 1 Normal Normal Normal Alive VD N N
146 30 Multi n 3˚cm N N N N 12 5.3 1 Normal Normal Normal Alive CS N N
147 23 Multi n Ncm N N N N 13 6.4 1.3 Normal Normal Normal Alive VD N N
148 23 Multi n Ncm N N N N 11.6 5 0.5 Normal Normal Normal Alive VD N N
149 26 Multi n Ncm N N N N 13.5 7.4 1.1 Normal Normal Normal Alive VD N N
150 27 Primi - Ncm N N N N 12.4 5.9 1 Normal Normal Normal Alive CS N N
151 21 Primi - Ncm N N N N 13 6.4 1.1 Normal Normal Normal Alive CS N N
152 22 Primi - Ncm N N N N 11.4 4.7 0.8 Normal Normal Normal Alive VD N N
153 22 Primi - Ncm N N N N 12.5 6.1 1 Normal Normal Normal Alive VD N N
154 20 Primi - Ncm N N N N 11.6 5 0.8 Normal Normal Normal Alive VD N N
155 19 Multi n Ncm N N N N 12 5.3 1.5 Normal Normal Normal Alive CS N N
156 25 Primi - Ncm N N N N 12.6 5.7 1.2 Normal Normal Normal Alive VD N N
157 23 Multi poor 2˚cm N N N N 13 6.4 1.4 Normal Normal Normal Alive VD N N
158 18 Primi - 0 N N N N 13.2 6.8 1.4 Normal Normal Normal Alive VD N N
159 20 Multi poor 0 N N N N 12.6 6.3 1.1 Normal Normal Normal Alive CS LBW Y
160 32 Primi - NCM N N N N 13.4 7.2 1.3 Normal Normal Normal Alive VD N N
161 23 Multi poor 0 N N N N 12.5 6.1 1.5 Normal Normal Normal Alive VD N Y
162 30 Multi n 3˚cm N N N N 11.5 4.8 1.3 Normal Normal Normal Alive VD N N
163 25 Multi poor 0 N N N N 12.5 6.1 1.5 Normal Normal Normal Alive CS N N
164 23 Primi - 0 N N N N 11.5 4.8 1.3 Normal Normal Normal Alive VD N N
165 20 Multi poor 0 N N N N 13.1 6.6 1.9 Normal Normal Normal Alive VD N N
166 22 Multi n 3˚cm N N N N 13 6.4 1.1 Normal Normal Normal Alive CS N Y
167 24 Primi - 0 N N N N 12.1 5.3 0.9 Normal Normal Normal Alive VD N N
168 31 Multi n 2 N N N N 11.4 4.9 0.6 Normal Normal Normal Alive VD N N
169 18 Primi - 3˚cm N N N N 11.6 5 0.5 Normal Normal Normal Alive CS N N
170 26 Multi n 0 N N N N 12.5 5.9 0.9 Normal Normal Normal Alive VD N N
171 22 Primi - 0 N N N N 13.1 6.6 1 Normal Normal Normal Alive CS N N
172 20 Multi n 0 N N N N 12.1 5.3 1.1 Normal Normal Normal Alive VD N N
173 24 Primi - 0 N N N GDM 13.4 7.2 1.2 Normal Normal Normal Alive CS N Y
174 26 Multi n 0 N N N N 12.6 6.3 0.9 Normal Normal Normal Alive VD LBW Y
175 25 Multi poor 2 N N N N 12.1 5.3 1.1 Normal Normal Normal Alive VD N N
176 21 Primi - 0 N N N N 11.6 5 0.7 Normal Normal Normal Alive VD N N
177 21 Primi - 0 N N N N 11.3 4.5 1 Normal Normal Normal Alive VD N N
178 23 Primi - 0 N N N N 12.2 5.5 1.2 Normal Normal Normal Alive CS N N
179 20 Multi n 2 N N N N 12.6 6.3 1.4 Normal Normal Normal Alive VD N N
180 27 Multi poor 0 N N N N 13.4 7.2 1.5 Normal Normal Normal Alive VD N N
181 19 Primi - 3˚cm N N N N 13.1 6.6 1 Normal Normal Normal Alive CS N N
182 23 Primi - 0 N N N N 13.6 7.6 1.8 Normal Normal Normal Alive VD N N
183 25 Multi n 0 N N N N 12.5 6.1 1.5 Normal Normal Normal Alive VD N N
184 21 Multi poor 3˚cm N N N N 13.5 7.4 1.3 Normal Normal Normal IUD VD
185 24 Multi poor 0 N N N N 13 6.4 1.1 Normal Normal Normal Alive VD LBW Y
186 22 Primi - 0 N N N N 12.6 6.3 0.9 Normal Normal Normal Alive CS N N
187 24 Multi poor 3˚cm N N N N 13.1 6.4 1.2 Normal Normal Normal Alive VD N N
188 19 Primi - 3˚cm N N N N 12.1 5.3 1 Normal Normal Normal Alive VD N N
189 20 Multi n 3˚cm N N N N 13 6.4 1.1 Normal Normal Normal Alive VD N N
190 23 Multi poor 0 N N N N 13.4 7.2 1.2 Normal Normal Normal Alive VD N N
191 22 Multi poor 0 N N N N 13.2 6.8 1.5 Normal Normal Normal Alive CS N N
192 25 Multi poor 3 N N N N 12.4 5.8 1.1 Normal Normal Normal Alive VD N N
193 20 Primi - 0 N N N N 12.6 6.3 1.6 Normal Normal Normal Alive VD N N
194 21 Primi - 0 N N N GDM 12.4 5.9 1.5 Normal Normal Normal Alive VD N N
195 23 Primi - 0 N N N N 12.5 6.1 1.2 Normal Abnormal Meningiomyelocele NND VD N Y
196 25 Multi n 0 N N N N 11.3 4.5 0.9 Normal Normal Normal Alive VD N N
197 20 Primi - 0 N N N N 12.6 6.4 1.1 Normal Normal Normal Alive VD N N
198 37 Multi n 0 N N N N 13.3 7 1 Normal Normal Normal IUD VD
199 24 Primi - 0 N N N N 12 5.3 0.9 Normal Normal Normal Alive VD N N
200 23 Multi n 0 N N N N 13.1 6.7 1.2 Normal Normal Normal Alive VD N N
201 19 Primi - 0 N N N N 12.5 6.1 1.2 Normal Normal Normal Alive VD N N
202 20 Multi poor 3˚cm N N N N 11.3 4.6 1.1 Normal Normal Normal Alive CS N N
203 24 Multi n 0 N N N N 11.6 5.2 1 Normal Normal Normal Alive CS N N
204 23 Multi poor 0 N N N GDM 11.6 5.2 0.8 Normal Normal Normal Alive CS N Y
205 24 Multi poor 2˚cm Y N N N 12.6 6 1.5 Normal Normal Normal Alive VD N N
206 36 Multi n 0 N N N N 13.6 7.6 1.4 Normal Normal Normal Alive CS N Y
207 19 Multi poor 0 N N N N 13.3 7.2 0.9 Normal Normal Normal Alive VD N N
208 27 Multi n 0 Y N N N 12.1 5.4 1.1 Normal Normal Normal Alive VD N N
209 22 Multi poor 0 N N N N 12.1 5.5 1.2 Normal Normal Normal Alive VD N N
210 28 Primi - 0 N N N N 13.4 7.1 1.7 Normal Normal Normal Alive for N Y
211 22 Multi poor 0 N N N N 12.3 5.6 0.2 Normal Normal Normal Alive VD N N
212 36 Multi n 3˚cm N N N N 12 5.1 0.9 Normal Normal Normal Alive VD N N
213 21 Multi n 0 N N N N 12.4 5.8 0.9 Normal Normal Normal Alive VD N N
214 26 Primi - 0 N N N N 13.1 6.7 1.2 Normal Normal Normal Alive VD N N
215 38 Primi - 0 N N N N 13.6 7.1 1.5 Normal Normal Normal Alive VD N N
216 23 Primi - 0 N N N N 11.6 5.2 1.7 Normal Normal Normal Alive VD N N
217 29 Primi - 0 N N N N 11.6 5.2 1.1 Normal Normal Normal Alive VD N N
218 35 Multi poor 0 N N N N 13 6.4 1.9 Normal Normal Normal Alive VD N N
219 35 Multi n 0 N N N DM 13.6 7.6 1.2 Normal Normal Normal Alive CS N N
220 27 Primi - 0 N N N GDM 11.4 4.6 0.8 Normal Normal Normal Alive VD N N
221 25 Multi poor 0 N N N GDM 12.1 5.6 1.8 Normal Normal Normal Alive CS N N
222 25 Primi - 0 N N N N 11.6 5.2 0.9 Normal Normal Normal Alive VD N N
223 18 Multi poor 0 N N N HD 11.4 4.6 0.8 Normal Normal Normal Alive CS N N
224 20 Primi - 0 N N Y N 12 5.1 0.9 Normal Abnormal cleftlip and cleftpalate Alive VD N Y
225 25 Primi - 0 N N N HD 12.1 5.3 1 Normal Normal Normal Alive For N Y
226 25 Primi - 0 N N Y GDM,EPI 13.2 6.8 1.2 Normal Normal Normal IUD CS
227 26 Primi - 3˚cm N N N N 12.1 5.3 1.1 Normal Normal Normal Alive VD N N
228 28 Primi - 0 N N N N 13.1 6.75 3.07 Normal Normal Normal Alive CS N N
229 23 Multi n 0 N N N N 12.6 6.3 1.2 Normal Normal Normal Alive CS N N
230 22 Primi - 0 N N N N 13.2 6.8 1.4 Normal Normal Normal Alive CS N N
231 20 Primi - 3˚cm N N N N 12.5 6.1 1 Normal Normal Normal Alive VD N N
232 22 Multi poor 2˚cm N N N N 12.1 5.3 0.9 Normal Normal Normal Alive VD N Y
233 22 Multi poor 0 N N N N 13.2 6.8 1.8 Abnormal Normal Anencephaly TOP MTP1
234 32 Multi n 0 N N N N 11.6 5 0.9 Normal Normal Normal Alive VD Y Y
235 22 Multi n 0 N N N N 12.4 5.9 1.2 Normal Normal Normal Alive VD Y Y
236 19 Primi - 3˚cm N N N N 13.4 7.2 1.4 Normal Normal Normal Alive VD N N
237 25 Multi poor 0 N N N N 13.6 7.6 1.7 Normal Normal Normal Alive VD N N
238 21 Primi - 3˚cm N N N N 13.2 6.8 1.2 Normal Normal Normal Alive VD Y Y
239 23 Primi - 0 N N N N 12.5 6.1 1.3 Normal Normal Normal Alive VD N N
240 21 Primi - 0 N N N N 13 6.4 1.5 Normal Normal Normal Alive VD N N
241 19 Multi poor 0 N N N N 12.4 5.9 1.1 Normal Normal Normal Alive CS N N
242 30 Multi poor 0 N N N N 12.5 6.1 1.1 Normal Normal Normal Alive CS N N
243 23 Multi n 0 N N N N 12.6 6.3 1.2 Normal Normal Normal Alive VD N N
244 20 Primi - 0 N N N N 12 5.3 1.1 Normal Normal Normal Alive VD N N
245 21 Primi - 0 N N N N 12.4 5.9 1.2 Normal Normal Normal Alive CS N N
246 19 Primi - 0 N N N N 13 6.4 1.5 Normal Normal Normal IUD VD
247 27 Multi poor 0 N N N N 13.6 7.6 1.6 Normal Normal Normal Alive VD N N
248 23 Multi n 3˚cm N N N N 11.6 5 0.9 Normal Normal Normal Alive CS N N
249 22 Primi - 0 N N N N 12.3 5.7 1 Normal Abnormal Hydrocephalus TOP MTP2
250 23 Primi - 0 N N N N 12.2 5.5 1 Normal Normal Normal Alive VD N N
251 20 Multi poor 0 N N N N 12.6 6.3 1.1 Normal Normal Normal Alive CS N Y
252 25 Multi poor 0 N N N N 13.1 6.6 1.4 Normal Normal Normal Alive CS LBW Y
253 22 Primi - 0 N N N N 13.2 6.8 1.3 Normal Normal Normal Alive CS LBW Y
254 23 Multi n 0 N N N N 13 6.4 1.5 Normal Normal Normal Alive VD N N
255 20 Multi n 0 N N N N 12.4 5.9 1.1 Normal Normal Normal Alive VD N N
256 30 Multi n 0 N N N N 12.2 5.5 1.1 Normal Normal Normal Alive VD N N
257 26 Multi poor 2˚cm N N N N 12 5.3 1.2 Normal Normal Normal Alive CS N N
258 23 Multi n 0 N N N N 12.1 5.3 1.1 Normal Normal Normal Alive VD N N
259 23 Multi poor 0 N N N N 11.6 5 0.9 Normal Normal Normal Alive VD N N
260 26 Multi n 0 N N N N 11.5 4.8 0.7 Normal Normal Normal Alive CS N N
261 28 Multi n 2˚cm N N N N 12 6.1 1.1 Normal Normal Normal Alive VD N N
262 23 Multi n 0 N N N N 12.5 6.1 1.2 Normal Normal Normal Alive VD LBW Y
263 25 Multi n 3˚cm N N N N 13.5 7.4 1.1 Normal Normal Normal Alive VD N N
264 26 Multi poor 0 Y N N N 13.1 6.6 1.3 Normal Normal Normal Alive VD N N
265 20 Primi - 0 N N N N 13.6 7.6 1.5 Normal Normal Normal Alive CS N N
266 19 Primi - 0 N N N N 13 6.4 1.1 Normal Normal Normal Alive VD N N
267 20 Multi n 0 N N N N 12.5 6.1 1.2 Normal Normal Normal Alive CS N N
268 28 Primi - 0 N N N N 12.4 5.9 1.3 Normal Normal Normal Alive VD N N
269 29 Multi poor 0 N N N N 12.3 5.7 1 Normal Normal Normal Alive CS N N
270 22 Primi - 0 N N N N 12.1 .5.3 1.1 Normal Normal Normal Alive VD N N
271 28 Multi n 0 N N N N 12 6.1 1.1 Normal Normal Normal Alive VD N N
272 20 Primi - 0 N N N N 12.2 5.5 1.2 Normal Normal Normal Alive CS N N
273 22 Primi - 0 N N N N 13 6.4 1.4 Normal Normal Normal Alive VD N N
274 22 Multi poor 0 N N N N 11.6 5 0.9 Normal Normal Normal Alive CS N N
275 28 Primi - 0 N N N N 13.4 7.2 1.6 Normal Normal Normal Alive VD N N
276 38 Multi poor 0 N N N N 12.6 6.3 1.4 Normal Normal Normal Alive CS N N
277 32 Primi - 0 N N N DM 12.1 5.3 1.1 Normal Normal Normal Alive CS N Y
278 25 Multi n 0 N N N N 12.5 6.1 1.2 Normal Normal Normal Alive VD LBW Y
279 26 Primi - 0 N N N N 11.6 5 0.9 Normal Normal Normal Alive CS LBW Y
280 22 Primi - 0 N N N N 12.2 5.5 1.2 Normal Normal Normal Alive VD N N
281 28 Multi n 2˚cm N N N N 13.2 6.8 1.6 Normal Normal Normal Alive CS N N
282 28 Multi n 0 N N N N 13 6.4 1.5 Normal Normal Normal Alive VD N N
283 25 Multi n 0 N N N N 12.2 5.5 1.1 Normal Normal Normal Alive VD N N
284 22 Multi n 0 N N N N 12.5 6.1 1 Normal Normal Normal Alive vD N N
KEYS TO MASTER CHART 
n Normal IUD- intrautepoor bad obstetric history  TOP- Termination of Pregnancy 
N- No NND- Neonatal death 
Y- Yes LBW- Lowbirth weight
VD- Vaginal delivery MTP 1 First trimester medical termination of pregnancy 
CS- cesarean section MTP2 Second trimester medical termination of pregnancy
For - forceps delivery 
HYS-Hysterotomy 
intrauterine death 
